NCT04442048 2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3 Completed
Clinical Trials
9 trialsNCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
NCT05118724 2025-06-15
ANTONIO
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT01539824 2024-11-25
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
Immodulon Therapeutics Ltd
Phase 2 Completed
NCT03711188 2024-04-29
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
Immodulon Therapeutics Ltd
Phase 2 Completed
NCT01559818 2023-06-22
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT01303172 2021-11-10
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Immodulon Therapeutics Ltd
Phase 2 Completed
NCT04137822 2020-08-14
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Impatients N.V. trading as myTomorrows
No longer available
NCT01308762 2012-12-06
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
Immodulon Therapeutics Ltd
Phase 1 Completed